Feature | October 31, 2013

Global Bifurcation Leader Tryton Medical Announces Events at TCT 2013

First results from the Tryton Side Branch Stent Pivotal IDE Trial presented in Late Breaking Clinical Trial session

stents biforcation clinical trial study cath lab tryton tct side branch

October 31, 2013 — Tryton Medical Inc., a developer of stents designed to treat bifurcation lesions, announced activities highlighting the latest data and experience with the Tryton Side Branch Stent at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (TCT 2013).
 
Martin Leon, M.D. and principal investigator of the study, presented the first results from the Tryton Side Branch Stent Pivotal IDE trial during the morning Late Breaking Clinical Trial session.
 
The Tryton Pivotal IDE trial was an international, randomized study that compares a Tryton Stent in the side branch to conventional provisional stenting (balloon angioplasty) in the side branch, with both study groups receiving a standard drug-eluting stent (DES) in the main vessel. The study, which is the first randomized U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal clinical trial to evaluate a dedicated bifurcation stent, enrolled 704 patients at 67 centers in North America and 11 countries throughout Europe and Israel. It is the largest coronary bifurcation study ever conducted and the first study to employ core lab angiographic (3-D and planar) and intravascular ultrasound (IVUS) analysis. 
 
In advance of the unveiling of the results from this first-in-class trial, Leon presented Left Main and Bifurcation Stenting: An Advanced Operator’s Workshop during Session VIII on Dedicated Bifurcation Stents. He presented on the topic of “The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results.”
 
Leon and Patrick Serruys, M.D. and Ph.D., chaired a symposium regarding the Tryton Side Branch Stent. At the symposium, clinicians further examined the clinical and angiographic outcomes from the IDE trial, reviewed the historic body of clinical evidence, presentred real-world Tryton Stent cases and provided perspectives on treating a broad spectrum of bifurcation anatomies. 
 
Additionally, the Tryton Stent was featured in the Challenging Cases forum and in Poster Abstract sessions:
 
  • Robin Kraak, M.D., hosted: “Treatment of complex coronary bifurcation lesion; ABSORB BVS in combination with Tryton short dedicated bifurcation stent” and “Treatment of complex coronary bifurcation lesion in a patient with acute ST elevation myocardial infarction; ABSORB BVS in combination with Tryton dedicated bifurcation stent.”
  • Balazs Berta, M.D., hosted “Trifurcational occlusion treated by dedicated bifurcation stent in ST-elevation myocardial infarction from transradial approach.”
  • Maik Grundeken, M.D., hosted “First Report on Long-term Clinical Results After Treatment of Coronary Bifurcation Lesions With the Tryton Dedicated Bifurcation Stent.”
 
For more information: www.trytonmedical.com

Related Content

News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
Subscribe Now